News | May 28, 2025
Granules India posts Q4 FY25 PAT at Rs. 152 Cr
The company reported sustained increase in formulations' share despite slowdown in productivity of Gagillapur facility
The company reported sustained increase in formulations' share despite slowdown in productivity of Gagillapur facility
Adjusted EBITDA positive at Rs. 3.1 crore despite investments in marketing, talent hiring and technology over the year
Facility also named 2025 ISPE Facility of the Year Winner for Social Impact - Unmet Medical Needs
Campaign empowers women to prioritise their health through thought provoking films, influencer-led campaigns, scientific and medical podcasts, survivor experiences, and digital awareness
Akums invested Rs. 272 crore in capital expenditure during FY25
YESINTEK is indicated for the treatment of adults and children from the age of 6 years and olde
The company recorded its quarterly consolidated revenue from operations at Rs. 61.22 crore in Q4 FY25
For the full year FY25, net profit soared 12x to Rs 345 crore
Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa's Recombinant Human Albumin in Europe
The company was awarded the insulins supply contract for a three-year period in 2022 through April 2025
Subscribe To Our Newsletter & Stay Updated
